Guardant Health, Inc. announced a strategic agreement with LabFlorida/SunDx Labs to provide residents of senior living communities access to Guardant Shield. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for colorectal cancer (CRC).
LabFlorida will serve as the exclusive distributor to senior living communities throughout Florida, offering concierge-style lab testing tailored for assisted and independent living and homebound patients. Colorectal cancer disproportionately affects older adults, yet seniors are often under-screened.
AmirAli Talasaz, Guardant Health co-CEO, stated that Shield has the potential to be revolutionary for senior living communities by making screening easy with a simple blood draw. This partnership aims to redefine preventative healthcare for residents, increase screening rates, and improve patient outcomes in this critical demographic.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.